Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Leukocytapheresis for ulcerative colitis]

K Sawada1, K Ohnishi, T Kosaka

  • 1Department of Internal Medicine 4, Hyogo College of Medicine, Nishinomiya, Japan.

Nihon Geka Gakkai Zasshi
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oxidative DNA damage in human esophageal cancer: clinicopathological analysis of 8-hydroxydeoxyguanosine and its repair enzyme.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2013
Same author

Esophageal replacement by colon interposition with microvascular surgery for patients with thoracic esophageal cancer: the utility of superdrainage.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2012
Same author

Acute lung injury following an esophagectomy for esophageal cancer, with special reference to the clinical factors and cytokine levels of peripheral blood and pleural drainage fluid.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2008
Same author

A variant form of hMTH1, a human homologue of the E coli mutT gene, correlates with somatic mutation in the p53 tumour suppressor gene in gastric cancer patients.

Journal of medical genetics·2004
Same author

Spontaneous tumorigenesis in mice defective in the MTH1 gene encoding 8-oxo-dGTPase.

Proceedings of the National Academy of Sciences of the United States of America·2001
Same author

[MTH1 functions in the prevention of the spontaneous mutations].

Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme·2001
Same journal

[MODIFIED BLUMGART SUTURING TECHNIQUE (NAGOYA METHOD) IN PANCREATICOJEJUNOSTOMY].

Nihon Geka Gakkai zasshi·2018
Same journal

[MODIFIED BLUMGART TECHNIQUE OF PANCREATOJEJUNOSTOMY（BLUMGART―DUMPLING METHOD)].

Nihon Geka Gakkai zasshi·2018
Same journal

[BLUMGART’S TYPE ANASTOMOSES;AN EMERGING TECHNIQUE FOR PANCREATICODUODENECTOMY].

Nihon Geka Gakkai zasshi·2018
Same journal

[WHAT WE CAN LEARN FROM A CASE OF MEDICAL MALPRACTICE―MEDICAL NEGLIGENCE CASE DISMISSED FOR INITIAL DIAGNOSIS OF BENIGN COLONIC POLYPS (THAT LATER TURNED CANCEROUS)].

Nihon Geka Gakkai zasshi·2018
Same journal

[WOUND CLOSURE METHODS FOR PREVENTION OF SURGICAL SITE INFECTION AND PATHOLOGIC SCARS－INCISION AND SUTURE METHODS FOR PREVENTION OF SSI, HYPERTROPHIC SCARS AND KELOID-].

Nihon Geka Gakkai zasshi·2018
Same journal

[PREFACE TO “WOUND CLOSURE METHODS FOR PREVENTION OF SURGICAL SITE INFECTION AND PATHOLOGIC SCARS ― INCISION AND SUTURE METHODS FOR PREVENTION OF SSI, HYPERTROPHIC SCARS AND KELOID ―”].

Nihon Geka Gakkai zasshi·2018
See all related articles

Leukocytapheresis (LCAP) effectively treats ulcerative colitis (UC) in 76% of patients unresponsive to conventional drugs, offering a safe alternative therapy with sustained remission. LCAP provides a valuable treatment option between medications and surgery.

Area of Science:

  • Gastroenterology
  • Immunology

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
  • Conventional therapies often yield insufficient responses in some UC patients.
  • Leukocytapheresis (LCAP) offers a potential therapeutic alternative.

Observation:

  • LCAP was administered to 38 UC patients with insufficient response to conventional drugs.
  • Therapy involved intensive (weekly for 5 weeks) and maintenance (monthly) phases.
  • Each LCAP session removed approximately 1 x 10(10) white blood cells.

Findings:

  • Clinical improvement was observed in 76% (29/38) of patients during intensive therapy.
  • Remission was maintained in 68.4% (26/38) during maintenance therapy.
  • Patients with excellent and moderate responses achieved average remissions of 2.5 years and 20 months, respectively.

Related Experiment Videos

  • No side effects were reported in clinical or blood examinations.

    • Implications:

    • LCAP demonstrates significant efficacy and safety as an alternative treatment for ulcerative colitis.
    • It offers a valuable therapeutic option between conventional drug therapies and surgical intervention.
    • Long-term remission achieved suggests LCAP's potential for sustained disease control in UC patients.